Premium
Emerging clinical concerns in the ageing haemophilia patient
Author(s) -
KONKLE B. A.,
KESSLER C.,
ALEDORT L.,
ANDERSEN J.,
FOGARTY P.,
KOUIDES P.,
QUON D.,
RAGNI M.,
ZAKARIJA A.,
EWENSTEIN B.
Publication year - 2009
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2009.02066.x
Subject(s) - haemophilia , medicine , disease , clotting factor , population ageing , intensive care medicine , hepatitis c , population , disease management , liver disease , pediatrics , immunology , pathology , environmental health , parkinson's disease
Summary. The availability of safe replacement clotting factor concentrates together with effective antiviral drugs to treat human immunodeficiency and hepatitis C viruses and the provision of care at designated haemophilia treatment centres have resulted in a new phenomenon in haemophilia management – the ageing patient. Today, increasing numbers of persons with haemophilia (PWH) are middle‐aged and older, and they face the same age‐related health issues as the general population. The impact of these risks on PWH is unclear, however, and there is a paucity of information about how to manage comorbidities in this patient population. This review focuses on five comorbidities that uniquely affect older PWH: cardiovascular disease, liver disease, cancer, renal disease and joint disease. Available research is summarized and potential management approaches are suggested.